Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Modulation of Immune Response Induced by Co-Administration of DNA Vaccine Encoding HBV Surface Antigen and HCV Envelope Antigen in BALB/c Mice

  • Nam, Sang-Hyun (Department of Pharmacology, National Institute of Toxicological Research, KFDA) ;
  • Park, Jae-Hyun (Department of Pharmacology, National Institute of Toxicological Research, KFDA) ;
  • Kang, Ju-Hye (Biologics Evaluation Department, KFDA) ;
  • Kang, Seog-Youn (Biologics Evaluation Department, KFDA) ;
  • Kim, Jae-Hong (Inflammatory Signaling Laboratory, Graduate School of Biotechnology, Korea University) ;
  • Kim, So-Young (Department of Pharmacology, National Institute of Toxicological Research, KFDA) ;
  • Ahn, Joon-Ik (Department of Pharmacology, National Institute of Toxicological Research, KFDA) ;
  • Park, Ki-Sook (Department of Pharmacology, National Institute of Toxicological Research, KFDA) ;
  • Chung, Hye-Joo (Department of Pharmacology, National Institute of Toxicological Research, KFDA)
  • Published : 2006.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Plasmid DNA vaccines encoding the hepatitis B virus (HBV) surface and hepatitis C virus (HCV) envelope antigens, respectively, were constructed, and attempt were made to find the possibility of a divalent vaccine against HBV and HCV. The expression of each plasmid in Cos-1 cells was confirmed using immunocytochemistry. To measure the induced immune response by these plasmids in vivo, female BALB/c mice were immunized intramuscularly with $100\;{\mu}g$ of either both or just one of the plasmids. Anti-HBV and HCV-specific antibodies and related cytokines were evaluated to investigate the generation of both humoral and cellular immune responses. As a result, specific anti-HBV and anti-HCV serum antibodies from mice immunized with these plasmids were observed using immunoblot. The levels of IL-2 and RANTES showing a $Th_{1}$ immune response were significantly increased, but there was no change in the level of IL-4 ($Th_{1}$ immune response) in any of the immunized groups. Compared with each plasmid DNA vaccine, the combined vaccine elicited similar immune responses in both humoral and cell-mediated immunities. These results suggest that the combined DNA vaccine can induce not only comparable immunity experimentally without antigenic interference, but also humoral and $Th_{1}$ dominant cellular immune responses. Therefore, they could serve as candidates for a simultaneous bivalent vaccine against HBV and HCV infections.

Keywords

References

  1. Beckebaum, S., Cicinnati, V. T., and Gerken, G., DNA-based immunotherapy: potential for treatment of chronic viral hepatitis? Rev. Med. Virol., 12, 297-319 (2002) https://doi.org/10.1002/rmv.359
  2. Decker, M. D., Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr. Infect. Dis. J., 20(Suppl), S10-8 (2001) https://doi.org/10.1097/00006454-200101000-00003
  3. Fried M. W. and Hoofnagle J. H., Therapy of hepatitis C. Semin. Liver. Dis., 15, 82-91 (1995) https://doi.org/10.1055/s-2007-1007265
  4. Geissler, M., Tokushige, K., Wakita, T., Zurawski, V. R. Jr., and Wands, J. R., Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine, 16, 857-867 (1998) https://doi.org/10.1016/S0264-410X(97)00236-3
  5. Hourvitz, A., Mosseri, R., Solomon, A., Yehezkelli, Y., Atsmon, J., and Danon, Y. L., Koren, R., and Shouval, D., Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. J. Viral. Hepat., 3, 37-42 (1996) https://doi.org/10.1111/j.1365-2893.1996.tb00079.x
  6. Jin, J., Yang, J. Y., Liu, J., Kong, Y. Y., Wang, Y., and Li, G. D., DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune reponses to both HCV and HBV. World J. Gastroenterol., 8, 505-510 (2002) https://doi.org/10.3748/wjg.v8.i3.505
  7. Ljungberg, K., Rollman, E., Eriksson, L., Hinkula, J., and Wahren, B., Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology, 302, 44-57 (2002) https://doi.org/10.1006/viro.2002.1547
  8. Krahn, M. D., John-Baptiste A., Yi, Q., Doria, A., Remis, R. S., Ritvo, P. and Friedman, S., Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine, 23, 1549-1558 (2005) https://doi.org/10.1016/j.vaccine.2004.09.023
  9. Lagging, L. M., Meyer, K., Hoft, D., Houghton, M., Belshe, R. B., and Ray, R., Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J. Virol., 69, 5859-5863 (1995)
  10. Liu, M., Acres, B., Balloul, J. M., Bizouarne, N., Paulm S., Slos, P., and Squiban, P., Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. U.S.A., 101, 14567- 14571 (2004)
  11. Major, M. E., Vitvitski, L., Mink, M. A., Schleef, M., Whalen, R. G., Trepo, C., and Inchauspe, G., DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J. Virol., 69, 5798–5805 (1995)
  12. Musacchio, A., Rodriguez, E. G., Herrera, A. M., Quintana, D., and Muzio, V., Multivalent DNA-based immunization against hepatitis B virus with plasmids encoding surface and core antigens. Biochem. Biophys. Res. Commun., 282, 442-446 (2001) https://doi.org/10.1006/bbrc.2001.4580
  13. Nakano, I., Maertens, G., Major, M. E., Vitvitski, L., Dubisson, J., Fournillier, A., Martyroff, G. D., Trepo, C., and Inchauspe. G., Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J. Virol., 71, 7101-7109 (1997)
  14. Pinto, A. R., Reyes-Sandoval, A., and Ertl, H. C., Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus. Cell. Immunol., 224,106-113 (2003) https://doi.org/10.1016/j.cellimm.2003.08.006
  15. Romagnani, S., T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Immunol., 85, 9-18 (2000) https://doi.org/10.1016/S1081-1206(10)62426-X
  16. Song, H. K., Noorchashm, H., Lin, T. H., Moore, D. J., Greeley, S. A., Caton, A. J., and Naji, A., Specialized CC-chemokine secretion by Th1 cells in destructive autoimmune myocarditis. J. Autoimmune, 21, 295-303 (2003) https://doi.org/10.1016/S0896-8411(03)00110-0
  17. Suh, D. J. and Jeong, S. H., Current status of hepatitis C virus infection in Korea. Intervirology, 49, 70-75 (2006) https://doi.org/10.1159/000087266
  18. Tedeschi, V., Akatsuka, T., Shih, J. W., Battegay, M., and Feinstone, S. M., A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2. Hepatology, 25, 459- 462 (1997) https://doi.org/10.1002/hep.510250234
  19. Wright, T. L. and Lau, J. Y., Clinical aspects of hepatitis B virus infection. Lancet, 324, 1340-1344 (1993)
  20. Yang, J. S., Kim, J. J., Hwang, D., Choo, A. Y., Dang, K., Maguire, H., Kudchodkar. S., Ramanathan, M. P., and Weiner, D. B., Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNVNY1999). J. Infect. Dis., 184, 809-816 (2001) https://doi.org/10.1086/323395
  21. Yap. I., Guan, R., and Chan, S. H ., Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein preliminary study on immunogenicity. Vaccine, 10, 439-442 (1992) https://doi.org/10.1016/0264-410X(92)90391-V